[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364142-105":59,"doc-detail-364142-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-estrogen-receptor-alpha-1-esr1-testing-patterns-and-results-for-erher2-metastatic-breast-cancer-in-the-united-states-20182024","Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2-metastatic breast cancer in the United States, 2018–2024","","Purpose of this retrospective observational cohort study is to quantify historical and recent ESR1 testing rates and determine when ESR1 mutations emerge during first-line (1L) treatment. Adult patients with confirmed HR+/HER2-negative metastatic breast cancer from 1/1/2018 to 6/30/2024 were analyzed using the Flatiron Health Research Database and Flatiron Health-Foundation Medicine mBC Clinico-Genomic Database. ESR1 test patterns and results were descriptively summarized across baseline and on-treatment intervals, including tissue and liquid biopsy timing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-estrogen-receptor-alpha-1-esr1-testing-patterns-and-results-for-erher2-metastatic-breast-cancer-in-the-united-states-20182024/364142/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-estrogen-receptor-alpha-1-esr1-testing-patterns-and-results-for-erher2-metastatic-breast-cancer-in-the-united-states-20182024/364142.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of analyzing ESR1 testing patterns in this study?","Question",{"text":112,"@type":113},"The study aims to understand historical and recent ESR1 testing rates and identify when ESR1 mutations emerge during first-line treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which data sources and patient population were used?",{"text":117,"@type":113},"The analysis used the Flatiron Health Research Database and the Flatiron Health-Foundation Medicine metastatic breast cancer Clinico-Genomic Database. Included were adults with confirmed HR+/HER2-negative metastatic breast cancer from 1/1/2018 to 6/30/2024.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about ESR1 mutation detection timing during first-line therapy?",{"text":121,"@type":113},"ESR1 mutations were detectable at any time interval during first-line treatment. Positivity increased from earlier specimens (baseline) to later time points during 1L, with the highest reported positivity in later intervals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364142,1790524096,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Breast Cancer Research and Treatment (2026) 219:8  \n[https://doi.org/10.1007/s10549-026-08060-x](https://doi.org/10.1007/s10549-026-08060-x)  \nRESEARCH  \nReal-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2-metastatic breast cancer in the United States, 2018–2024  \nJane Meisel1 · Tim Pham2 · Clara Chen2 · Ayush Kris3 · James Roose3  \nReceived: 10 February 2026 / Accepted: 14 August 2026 © The Author(s) 2026  \nAbstract  \nPurpose To understand historical and recent ESR1 testing rates, and when ESR1 mutations emerge during first-line (1 L) treatment.  \nMethods This retrospective, observational cohort study used the Flatiron Health Research Database (FHRD) and the Flatiron Health-Foundation Medicine metastatic breast cancer (mBC) Clinico-Genomic Database (CGDB). Adult patients with a confirmed diagnosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative mBC from 1/1/2018 to 6/30/2024 were included. ESR1 testing patterns and test results were descriptively analyzed.  \nResults Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L. The percentage of patients who had an ESR1 test result reported during 1 L increased over time (11% in 2018-19, 19% in 2020-21, 22% in 2022-24) . Median time from 1 L start to first ESR1 test was 7.4 months (mos) among tested patients. A positive test result was reported for 29/222 (13%) patients tested at baseline and 240/1355 (18%) tested during 1 L. Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10–84) days. Focusing on time periods wherein specimens were provided, ESR1 test positivity was 6.7%(76/1,127) for specimens provided at baseline, 23%(15/65) for specimens provided 9 to 12 months into 1L therapy, 38%(26/69) for those provided 15 to 18 months into 1L, and 40%(38/94) for those provided from 18 to 24 months into 1L.  \nConclusions ESR1 mutations can be detected at any time interval during 1L.  \nClinical trial number Not applicable.  \nKeywords HR+/HER2- · Metastatic breast · ESR1 mutation  \n James Roose [james.roose@flatiron.com](james.roose@flatiron.com)  \nJane Meisel  \n[jane.l.meisel@emory.edu](jane.l.meisel@emory.edu)  \nTim Pham  \n[timpham123@gmail.com](timpham123@gmail.com)  \nClara Chen  \n[ying.chen26@astrazeneca.com](ying.chen26@astrazeneca.com)  \nAyush Kris  \n[ayush.kris@flatiron.com](ayush.kris@flatiron.com)  \n1 Department of Hematology and Medical Oncology, Emory Winship Cancer Institute, Emory University, Atlanta, GA, USA  \n2 AstraZeneca, Gaithersburg, MD, USA  \n3 Flatiron Health, New York, NY, USA  \nIntroduction  \nFemale breast cancer (BC) is the second most common cancer: in 2025, an estimated 316,950 women in the US will be diagnosed with BC, and an estimated 42,170 women will die from the disease [1–3] . Estrogen receptor alpha (ER⍺), encoded by the ESR1 gene, and its cognate ligand estrogen are key factors in the development and progression of luminal breast cancers. Breast cancers characterized by ER expression (ER+), and a lack of HER2 overexpression or amplification (ER+/HER2-), are the most common BC subtype and represent approximately 70% of all BC cases, and after relapse, account for most BC-related deaths [4, 5] .  \nEndocrine therapies (ET) that disrupt ER signaling in ER-positive breast cancers are effective targeted treatments  \nin both early-stage and metastatic BC (mBC) [2, 6] . However, many patients eventually develop resistance to ET and progress on first-line (1 L) therapy within 2–3 years [7–9] . Mutations in the ESR1 gene, particularly in the hormone binding domain, have been shown to be associated with development of resistance to ET and with poor prognosis and worse outcomes [10–14], but are rare at mBC diagnosis [15], and detected in less ","cbCairqvmxo7s8En","https://ap.wps.com/l/cbCairqvmxo7s8En","pdf",1343105,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Epidemiology and biology of ER+/HER2- disease\n## Endocrine therapy resistance and ESR1 mutations\n## Clinical evidence and guideline updates\n## Treatment switching strategies","[{\"question\":\"What is the main purpose of analyzing ESR1 testing patterns in this study?\",\"answer\":\"The study aims to understand historical and recent ESR1 testing rates and identify when ESR1 mutations emerge during first-line treatment.\"},{\"question\":\"Which data sources and patient population were used?\",\"answer\":\"The analysis used the Flatiron Health Research Database and the Flatiron Health-Foundation Medicine metastatic breast cancer Clinico-Genomic Database. Included were adults with confirmed HR+/HER2-negative metastatic breast cancer from 1/1/2018 to 6/30/2024.\"},{\"question\":\"What did the study find about ESR1 mutation detection timing during first-line therapy?\",\"answer\":\"ESR1 mutations were detectable at any time interval during first-line treatment. Positivity increased from earlier specimens (baseline) to later time points during 1L, with the highest reported positivity in later intervals.\"}]","Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2-metastatic breast cancer in the United States, 2018–2024 | PDF",1790155946,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e96ba66c41ac8e32705a77f8361bbb2.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83fb0489ae645edd8dd2919e30b7b6d2.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5a097d1662148f79c2ab2d4dd787aaa.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a8bbf334319f83a3ed75b046c434d91.webp",980,1301]